Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.51 |
| ▸ | CTSD | P07339 | 3/20 | 0.51 |
| ▸ | FLT3 | P36888 | 5/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698955 | 0.85 | BACE1 (0.50) | BACE1CTSDCTSB | |
| SCHEMBL5579626 | 0.84 | FLT3 (0.46) | FLT3RXFP1MEN1ALDH1A1RAB9A | |
| SCHEMBL5579615 | 0.84 | FLT3 (0.46) | FLT3RXFP1MEN1ALDH1A1RAB9A | |
| SCHEMBL3353021 | 0.84 | BACE1 (0.46) | BACE1CTSDCTSB | |
| SCHEMBL13308210 | 0.84 | BACE1 (0.46) | BACE1CTSDCTSB | |
| SCHEMBL3353030 | 0.84 | BACE1 (0.46) | BACE1CTSDCTSB | |
| SCHEMBL5130125 | 0.81 | FLT3 (0.47) | FLT3RXFP1MEN1ALDH1A1RAB9A | |
| SCHEMBL3348573 | 0.79 | BACE1 (0.58) | BACE1CTSDCTSB | |
| SCHEMBL5374554 | 0.78 | BACE1 (0.58) | BACE1CTSDCTSB | |
| SCHEMBL5379637 | 0.78 | BACE1 (0.61) | BACE1CTSDCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 249/4885FLT3 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.